Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with high morbidity and
mortality worldwide. To date, limited therapeutic achievements targeting cell proliferation …

Pancreatic ductal adenocarcinoma (PDA) exhibits one of the poorest prognosis of all solid
tumours and poses an unsolved problem in cancer medicine. Despite the recent success of …

Pancreatic ductal adenocarcinoma (PDA) is among the deadliest cancers in the United
States and in the world. Late diagnosis, early metastasis and lack of effective therapy are …

Around 95% of patients diagnosed with pancreatic cancer will die of their disease within 5
years, three quarters within a year. The major hurdle in improving prognosis is the lack of a …

The tumor associated stroma has been described in recent years as being complicit in tumor
growth in pancreatic cancer. The stroma hosts a variety of components of both cellular and …

Recent studies have shed new light on the contribution of the pancreatic cancer
fibroinflammatory stroma to pancreatic cancer biology. Additional studies are needed to …

Pancreatic cancer (PC) is the most aggressive type of common cancers, and in 2014, nearly
40000 patients died from the disease in the United States. Pancreatic ductal …

Pancreatic ductal adenocarcinoma (PDAC) has one of the worst outcomes among cancers
with a 5-years survival rate of below 10%. This is a result of late diagnosis and the lack of …

Pancreatic ductal adenocarcinoma (PDAC) remains a lethal cancer. The poor prognosis
calls for a more detailed understanding of disease biology in order to pave the way for the …

Recent studies have demonstrated that the interaction between the cancer and the stroma,
play a key role in the development of pancreatic cancer. The desmoplasia, which consists of …